HodgsonSH, MansattaK, MallettG, et al.What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2. Lancet Infect Dis, 2021; 21:e26–e35; doi: 10.1016/S1473-3099(1020)30773-30778.
2.
BardaN, DaganN, CohenC, et al.Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: An observational study. Lancet, 2021; 398:2093–2100; doi: 2010.1016/S0140-6736(2021)02249-02242.
3.
Lopez BernalJ, AndrewsN, GowerC, et al.Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: Test negative case-control study. BMJ, 2021; 373:n1088; doi: 10.1136/bmj.n1088.
4.
Levine-TiefenbrunM, YelinI, KatzR, et al.Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine. Nat Med, 2021; 27:790–792; doi: 710.1038/s41591-41021-01316-41597.
5.
BraeyeT, CornelissenL, CatteauL, et al.Vaccine effectiveness against infection and onwards transmission of COVID-19: Analysis of Belgian contact tracing data, January-June 2021. Vaccine, 2021; 39:5456–5460; doi: 5410.1016/j.vaccine.2021.5408.5060.
6.
HossainMM, SultanaA, PurohitN. Mental health outcomes of quarantine and isolation for infection prevention: A systematic umbrella review of the global evidence. Epidemiol Health, 2020; 42:e2020038; doi: 10.4178/epih.e2020038.
7.
KaraivanovA, LuSE, ShigeokaH, et al.Face masks, public policies and slowing the spread of COVID-19: Evidence from Canada. J Health Econ, 2021; 78:102475; doi: 10.1016/j.jhealeco.2021.102475.
8.
KausarS, Said KhanF, Ishaq Mujeeb Ur RehmanM, et al.A review: Mechanism of action of antiviral drugs. Int J Immunopathol Pharmacol, 2021; 35:20587384211002621; doi: 10.1177/20587384211002621.
9.
BojadzicD, AlcazarO, ChenJ, et al.Small-molecule inhibitors of the coronavirus spike: ACE2 protein-protein interaction as blockers of viral attachment and entry for SARS-CoV-2. ACS Infect Dis, 2021; 7:1519–1534; doi: 1510.1021/acsinfecdis.1511c00070.
WeisblumY, SchmidtF, ZhangF, et al.Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. Elife, 2020; 9:e61312; doi: 10.7554/eLife.61312.
12.
DiPiazzaAT, GrahamBS, RuckwardtTJ. T cell immunity to SARS-CoV-2 following natural infection and vaccination. Biochem Biophys Res Commun, 2021; 538:211–217; doi: 10.1016/j.bbrc.2020.1010.1060.
13.
KohlerH, NaraP. A novel hypothesis for original antigenic sin in the severe disease of SARS-CoV-2 infection. Monoclon Antib Immunodiagn Immunother, 2020; 39:107–111; doi: 110.1089/mab.2020.0029.
14.
BrownEL, EssigmannHT. Original antigenic sin: The downside of immunological memory and implications for COVID-19. mSphere, 2021; 6:e00056–e00021; doi: 00010.01128/mSphere.00056-00021.
15.
Kieber-EmmonsT, BrownE, NaraP, et al.Expert panel discussion on antigenic sin. Monoclon Antib Immunodiagn Immunother, 2021; 40:203–209; doi: 210.1089/mab.2021.0047.
16.
KoyamaS, IshiiKJ, CobanC, et al.Innate immune response to viral infection. Cytokine, 2008; 43:336–341; doi: 310.1016/j.cyto.2008.1007.1009.
17.
ZhangQ, WangD. Assessing the role of voluntary self-isolation in the control of pandemic influenza using a household epidemic model. Int J Environ Res Public Health, 2015; 12:9750–9767; doi: 9710.3390/ijerph120809750.
18.
SoleimanpourS, YaghoubiA. COVID-19 vaccine: Where are we now and where should we go?. Expert Rev Vaccines, 2021; 20:23–44; doi: 10.1080/14760584.14762021.11875824.
